Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is positioning itself at the forefront of the next wave of DNA damage response (DDR) cancer therapies, moving beyond established PARP inhibitors into a novel class targeting the PNKP enzyme. The company was featured in a BioMedWire editorial examining the rapidly expanding DDR inhibitor market, where new drug classes are emerging to address resistance and broaden therapeutic options. Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology and is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target a DNA repair enzyme involved in multiple repair pathways.
Preclinical data highlighted in the editorial show that ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while demonstrating a favorable toxicity profile. This positions the therapy as a potential candidate for cancers with unmet need, particularly those with PTEN mutations, which are common in various solid tumors. The company is also making progress in manufacturing scale-up, IND-enabling studies, and planning for first-in-human clinical development, supported by its proprietary SynoGraph causal AI platform through subsidiary Inka Health.
The DDR inhibitor market is attracting significant attention, with major players like AstraZeneca plc (NYSE: AZN) and emerging biotechs such as Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD), and Foghorn Therapeutics Inc. (NASDAQ: FHTX) also active in the space. Onco-Innovations’ focus on PNKP, a key enzyme in both single-strand break repair and base excision repair, could offer a differentiated approach to overcoming resistance seen with PARP inhibitors. The company’s technology is based on patented innovations from the University of Texas MD Anderson Cancer Center and others.
“Onco-Innovations is targeting a novel DDR target with a differentiated technology platform,” the editorial noted, emphasizing the potential of PNKP inhibition to address a broader range of tumors. The company’s SynoGraph AI platform, which analyzes causal relationships in biological data, is expected to accelerate target identification and optimize clinical trial design. Onco-Innovations is headquartered in Canada and is dedicated to cancer research and treatment, with a mission to pursue prevention and treatment through innovative solutions.
For more information, visit the company’s newsroom at https://ibn.fm/ONNVF. The full press release is available at https://ibn.fm/HH1VP.
